SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Everson G. Treatment of patients with hepatitis C virus on the waiting list. J Hepatol 2005; 42: 456462.
  • 2
    Forns X, Navasa M, Rodes J. Treatment of HCV infection in patients with advanced cirrhosis. Hepatology 2004; 40: 498.
  • 3
    Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255262.
  • 4
    Iacobellis A, Siciliano M, Perri F, Annicchiarico BE, Leandro G, Caruso N, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007; 46: 206212.
  • 5
    Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8: 350355.
  • 6
    Lavillette D, Morice Y, Germanidis G, Donot P, Soulier A, Pagkalos E, et al. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol 2005; 79: 60236034.
  • 7
    Yu MY, Bartosch B, Zhang P, Guo ZP, Renzi PM, Shen LM, et al. Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci U S A 2004; 101: 77057710.
  • 8
    Feray C, Gigou M, Samuel D, Thiers V, Bernuau J, Bismuth H, et al. Hepatitis C (HCV) and hepatitis B (HBV) in patients with fulminant hepatitis [abstract]. Hepatology 1991; 14: 130A.
  • 9
    Krawczynski K, Alter M, Tankersley D, Beach M, Robertson B, Lambert S, et al. Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis 1996; 173: 822828.
  • 10
    Davis G, Nelson D, Terrault N, Pruett T, Schiano T, Fletcher C, et al. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (civacir) in liver transplant recipients. Liver Transpl 2005; 11: 941949.
  • 11
    Schiano TD, Charlton M, Younossi Z, Galun E, Pruett T, Tur-Kaspa R, et al. Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl 2006; 12: 13811389.
  • 12
    Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: 680687.
  • 13
    Shergill AK, Khalili M, Straley S, Bollinger K, Roberts JP, Ascher NA, et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005; 5: 118124.
  • 14
    Reddy R, Fried M, Dixson R, Martin P, Torres M, Weppler D, et al. Interferon alfa-2b and ribavirin vs. placebo in early treatment in patients transplanted for hepatitis C end-stage liver disease: results of a multicenter randomized trial. Gastroenterology 2002; 122: 632A.
  • 15
    Mazzaferro V, Tagger A, Schiavo M, Regalia E, Pulvirenti A, Ribero ML, et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc 2001; 33: 13551357.
  • 16
    Sugawara Y, Makuuchi M, Matsui Y, Kishi Y, Akamatsu N, Kaneko J, et al. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 2004; 78: 13081311.
  • 17
    Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005; 41: 289298.
  • 18
    Singh N, Gayowski T, Wannstedt CF, Shakil AO, Wagener MM, Fung JJ, et al. Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation 1998; 65: 8286.
  • 19
    Sheiner P, Boros P, Klion F, Thung S, Schluger L, Lau J, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998; 28: 831838.
  • 20
    Kuo A, Lan B, Feng S, Terrault N. Long-term histologic effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection. Liver Transpl. In press.
  • 21
    Castells L, Esteban JI, Bilbao I, Vargas V, Allende H, Ribera E, et al. Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV-infected patients. Antiviral Ther 2006; 11: 10611070.
  • 22
    Zimmermann T, Bocher WO, Biesterfeld S, Zimmermann A, Kanzler S, Greif-Higer G, et al. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. Transpl Int 2007; 20: 583590.
  • 23
    Bzowej N, Nelson D, Thommes J, Hamzeh F, Charlton M. A randomized controlled trial of prophylactically administered peginterferon alfa-2a plus ribavirin vs no prophylaxis following orthotopic liver transplantation for hepatitis C: a report of initial safety and tolerability [abstract]. Hepatology 2006; 44(suppl 1): 188A.
  • 24
    Wiesner R, Sorrell M, Villamil F, and the International Liver Transplantation Society Expert Panel. Report of the First International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1S9.
  • 25
    Wang R, Kim D, Yao F, Roberts J, Terrault N. Long-term efficacy of different regimens of combination hepatitis B immunoglobulin (HBIG) and antivirals in preventing HBV recurrence post-transplantation [abstract]. Hepatology 2005; 42: A491.
  • 26
    Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274287.
  • 27
    Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8: 679687.
  • 28
    Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo G, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007; 46: 459465.
  • 29
    Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006; 6: 15861599.
  • 30
    Oton E, Barcena R, Moreno-Planas JM, Cuervas-Mons V, Moreno-Zamora A, Barrios C, et al. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose peg-interferon and ribavirin. Am J Transplant 2006; 38: 24992501.
  • 31
    Lodato F, Berardi S, Gramenzi A, Mazzella G, Lenzi M, Morelli MC, et al. Peg-interferon alfa-2b and ribavirin for the treatment of genotype 1 hepatitis C recurrence after liver transplantation. Aliment Pharmacol Ther 2008; 28: 450457.
  • 32
    Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Liver Transpl 2008; 14: 5358.
  • 33
    Sharma P, Marrero JA, Fontana RJ, Greenson JK, Conjeevaram H, Su GL, et al. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl 2007; 13: 11001108.
  • 34
    Samuel D, Bizollon T, Feray C, Roche B, Ahmed S, Lemonnier C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124: 642650.
  • 35
    Stanca CM, Fiel MI, Kontorinis N, Agarwal K, Emre S, Schiano TD. Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin. Transplantation 2007; 84: 180186.
  • 36
    Berardi S, Lodato F, Gramenzi A, D'Errico A, Lenzi M, Bontadini A, et al. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? Gut 2007; 56: 237242.
  • 37
    Kontorinis N, Agarwal K, Elhajj N, Fiel MI, Schiano TD. Pegylated interferon-induced immune-mediated hepatitis post-liver transplantation. Liver Transpl 2006; 12: 827830.
  • 38
    Cholongitas E, Samonakis D, Patch D, Senzolo M, Burroughs AK, Quaglia A, et al. Induction of autoimmune hepatitis by pegylated interferon in a liver transplant patient with recurrent hepatitis C virus. Transplantation 2006; 81: 488490.
  • 39
    Thomas RM, Brems JJ, Guzman-Hartman G, Yong S, Cavaliere P, Van Thiel DH. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003; 9: 905915.
  • 40
    Tekin F, Gunsar F, Karasu Z, Akarca U, Ersoz G. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics. Aliment Pharmacol Ther 2008; 27: 10811085.
  • 41
    Castells L, Vargas V, Allende H, Bilbao I, Luis Lazaro J, Margarit C, et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005; 43: 5359.